Finoriq research workspace

Revolution Medicines, Inc. (RVMD) Historical Metrics

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted. Review RVMD valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Company

Revolution Medicines, Inc. (RVMD)

Ticker

RVMD

Market Cap

$38.7B

Latest Price

$181.88

Industry

Biotech & Pharma

Open insider transactions

Revolution Medicines, Inc. (RVMD) Current Valuation Metrics

Static valuation preview for Revolution Medicines, Inc. (RVMD). Market data retrieved 2026-07-08. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.